Altana Pharma Ag

Amgen Research (munich) Gmbh

Takeda Gmbh

Takeda Pharmaceutical Company Limited

Amgen Research Gmbh

Wolfram Steinhilber

Thomas Boehm

Michael Molhoj

Jeffrey A Whitsett

Pernille Dybendal Pedersen

Markus Rast

Peter Skufca

Jürgen Volz

Thomas Urbig

Wolfgang Ise

Christian De Muynck

Gerhard Becker

R&uuml;diger Nave

Ann Marie Levine

Thomas R Korfhagen

Reinhold Schmidt

Andreas G&uuml;nther

Jurgen Volz

The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least about 20 mg/ml, a tonicity modifier and a buffer, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.

Liquid formulation comprising GM-CSF neutralizing compound

The present invention relates to aqueous formulations comprising at least 20 mg/ml of a compound neutralizing GM-CSF, a lyoprotectant and an amino acid and/or a buffer. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of lyophilization, storage and reconstruction. In a preferred aspect, the formulation, e.g. after reconstruction, is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.

Lyophilized formulation comprising GM-CSF neutralizing compound

Recombinant surfactant protein A and pharmaceutical compositions based thereon are useful for the prevention or treatment of pulmonary infection and inflammation.

Recombinant SP-A for the treatment or prevention of pulmonary infection and inflammation

Methods for determining the strongly hydrophobic pulmonary surfactant protein SP-C, SP-C specific antibody and a reagent kit for carrying out the methods are described.

Determination of the hydrophobic pulmonary surfactant protein SP-C

This-layer chromatography is used to separate, identify and quantity hydrophobic protein, hydrophobic protein fragment, hydrophobic modified protein and hydrophobic peptide. A method is thus provided for determination of proteins and peptides which, due to their low solubility in an aqueous solvent system, cannot be determined by conventional methods, such as ELISA, which are based on aqueous solvent systems.

Process for separating and analyzing hydrophobic proteins using thin layer chromatography

Growing community of inventors

Stockach, Germany

Wolfram Steinhilber